Targeted molecular therapy for neuroblastoma

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
Pillar, Laboratory, NSCLC, Liquid biopsy, AMP, IVD, Bandwidth (signal processing), Microsatellite instability, Automation, MSI, Neoplasm, Research, Microdissection, AM, Beckman Coulter, Detection, Chemistry, Test management, UMI, RUO, Methylation, NGS, Targeted molecular therapy for neuroblastoma, CRC, Health care, Partnership, HRD, Urinary cell-free DNA, Column, Pension fund, Medical imaging, Instrumentation, Multiplexing

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Key Points: 
  • NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).
  • "Pillar Biosciences is committed to developing the data necessary to support the quality, accuracy and value of our leading IVD & RUO kitted products which can be used locally by laboratories to perform NGS sequencing," said Randy Pritchard, CEO of Pillar Biosciences, Inc. "We are proud to present these data in partnership with our collaborators at this year's AMP Annual Meeting as we continue to enable more laboratories globally with NGS assays that can be performed in a low-cost, high-multiplexed manner, thus enabling actionable, accessible NGS profiling results."
  • The scientific data presented at AMP will focus on Pillar Biosciences oncoReveal™ Research-Use-Only (RUO) kitted NGS products for liquid biopsy (LBx), HRD, methylation, solid tumor and automation.
  • Localized NGS-based Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Patient Care in Oncology (Room 251F: 8:00-8:50 AM MDT)
    Highly Accurate and Automated NGS assays for Efficient Localized LBx and TBx Clinical Testing in Oncology (Room 251F: 9:00-9:51 AM MDT)
    Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for The Targeted Characterization of CRC & NSCLC Samples (Poster Number: ST120)
    Robust Low Frequency Somatic Variant Detection in cfDNA Using a SLIMamp® Based Liquid Biopsy Assay (Poster Number: ST035)
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (Poster Number: ST107)
    Automation of The Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System (Poster Number: ST029)
    QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection (Poster Number: TT007)
    To UMI or Not to UMI: Obtaining Robust Low-Frequency Variant Identification for Liquid Biopsy with a SLIMamp-Based NGS Chemistry Without Molecular Barcoding (Poster Number: ST145)
    Robust Bioinformatic Method for Estimating Tumor Content in cfDNA Using Denoised Target Sequencing (Poster Number: I031)
    Pillar Biosciences oncoReveal methylQuant Panels: Accurate and Easy-to-Use Methylation NGS Assays Leveraging SLIMamp Technology (Poster Number: ST031)
    oncoReveal Fusion LBx: Single-Tube Multiplexed PCR-Based NGS assay for Detection of Multiple Gene Fusions from Cell Free RNA (Poster Number: ST041)
    Robust Detection of Copy Number Amplifications Using Pillar's oncoReveal™ Core LBx Panel with Low Input from Liquid Biopsy Samples (Poster Number: I011)
    Poster and abstract summaries of this research will be available onsite at Pillar Biosciences' booth #619.

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023
Bispecific monoclonal antibody, Metalloproteinase, Therapy, Liver, Cytokine, MDNA, Poster, IL13RA2, Immunotherapy, Neoplasm, Brain, Society, TME, Breast, Patient, Toxicity, TSX, Targeted molecular therapy for neuroblastoma, Pharmaceutical industry, Medical imaging, Vaccine, Cancer

TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data demonstrating proof of concept for the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company’s development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) held in San Diego, CA, from November 1-5, 2023.

Key Points: 
  • “The results presented today demonstrates proof of concept with MDNA113, our first T-MASK candidate specifically designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R⍺2.
  • MDNA113 has high selectivity and affinity for the IL-13 decoy receptor IL-13Rα2, a tumor associated antigen expressed by many aggressive solid tumors.
  • MDNA113 is fused via a protease sensitive linker (“PSL”) to MDNA223, containing a not-alpha, beta-enhanced IL-2 Superkine fused to anti-PD1 antibody.
  • A copy of the poster will be posted to the “ Events and Presentations ” page of Medicenna’s website following the conclusion of the meeting.

ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCE

Retrieved on: 
Thursday, November 2, 2023
SMN2, Medical Affairs Bureau, Real-time, IVD, AMP, Bio-Techne, Doctor of Philosophy, RUO, FMR1, ESR1, SMN1, Cystic fibrosis, Frequency, Workflow, Diagnosis, BCR-ABL, Patient, Neoplasm, Targeted molecular therapy for neuroblastoma, Pharmaceutical industry, Medical imaging

MINNEAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology (AMP), to be held November 14-18 in Salt Lake City, Utah. Attendees can learn about Asuragen's new products and innovations through a series of corporate workshops and poster presentations.

Key Points: 
  • Attendees can learn about Asuragen's new products and innovations through a series of corporate workshops and poster presentations.
  • "We look forward to sharing new data that reinforces our commitment to more equitable healthcare, comprehensive genetic coverage, and novel approaches to cancer monitoring and management."
  • In addition, Dr. Jordan Laser, Senior Director, Clinical and Medical Affairs for Bio-Techne's Diagnostics and Genomics Segment, will be recognized at the conference with the AMP Meritorious Service Award for his work to promote AMP as a member of the association.
  • AmplideX® to the Rescue: One easy-to-implement test workflow enabling repeat expansion resolution, copy number assessment, and highly multiplexed variant detection.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Global Precision Oncology Research Report 2023-2031: The Role of AI and Machine Learning in Precision Oncology and Rise of Targeted Therapies - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 7, 2023
Oncology, Health, Technology, Genetics, Artificial Intelligence, Biotechnology, DNA, Circulating tumor DNA, Liquid, Prevalence, Genomics, Neoplasm, Cancer, ML, Targeted molecular therapy for neuroblastoma, Gene expression, Biomarker, USD, Traction, Patient, Machine learning, Algorithm, Blood, Medicine, Artificial intelligence, Growth, Diagnosis, Medical imaging, Pharmaceutical industry

The global precision oncology market was valued at USD 98.2 billion in 2022, driven by the increasing prevalence of cancer across the globe.

Key Points: 
  • The global precision oncology market was valued at USD 98.2 billion in 2022, driven by the increasing prevalence of cancer across the globe.
  • Precision oncology offers a paradigm shift in cancer care by leveraging molecular information to guide personalized treatment decisions.
  • Integration of Artificial Intelligence and Machine Learning: The use of artificial intelligence (AI) and machine learning (ML) algorithms in precision oncology is growing rapidly.
  • Integration of Precision Oncology into Clinical Practice: The adoption of precision oncology approaches in routine clinical practice is expanding.

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023
Neuroblastoma, Abstract, MBBS, Metastasis, EANM, Glomus tumor, Targeted molecular therapy for neuroblastoma, MBA, DNB, Nuclear medicine, PET-CT, Perspective, European Association of Nuclear Medicine, CATX, MD, Patient, Molina Healthcare, FMRI, Cancer, Therapy, NYSE, Targeted alpha-particle therapy, Pharmaceutical industry, Safety, IOWA

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

Retrieved on: 
Monday, August 7, 2023
Genetics, Pharmaceutical, Health, Molecule, GSK, Asthma, Therapy, NASH, Targeted molecular therapy for neuroblastoma, FSHD, CNS, Development, PIN, SOD1, PALISADE, Facioscapulohumeral muscular dystrophy, Patient, Serum, Fatty liver disease, Webcast, RNA interference, ALS, Gene, Disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023.
  • The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m.
  • ET to discuss the results.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

Retrieved on: 
Thursday, June 1, 2023
Research, Genetics, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, Molecule, Arrowhead, Idiopathic pulmonary fibrosis, Asthma, Research and development, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, Serum, CTA, Targeted molecular therapy for neuroblastoma, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, Hepatocyte, University of Kansas Medical Center, Small RNA, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, Liver, RNA interference, ASCVD, Adipose tissue, Moyamoya disease, R, Goldberg, ALS, Gene, Medical device, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m.
  • ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “In 2017 we had optimized the TRiM™ platform for hepatocyte delivery, but we had yet to advance any candidates into clinical studies.
  • (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and Ira Goldberg, M.D.

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

Retrieved on: 
Wednesday, April 12, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Medical Devices, Research, Genetics, Science, Clinical Trials, Molecule, Arrowhead, Rat, Research and development, Central nervous system, Asthma, University, Therapy, Hypertriglyceridemia, File, Leonard M. Miller School of Medicine, CTA, Targeted molecular therapy for neuroblastoma, Brain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NYU Langone Health, CNS, University of Kansas Medical Center, SOD1, Arrowhead Pharmaceuticals, Patient, Primate, Fatty liver disease, RNA interference, Moyamoya disease, R, Benatar, ALS, Vaccine, Pharmaceutical industry, ASCVD

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m.
  • ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.
  • The R&D Day will feature presentations by three key opinion leaders: Ira Goldberg, M.D.
  • A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Paragon Genomics Partners with Devyser to Expand CleanPlex® Technology Distribution in Italy

Retrieved on: 
Wednesday, March 1, 2023
Paragon, Tao, NGS, Cardiology, Targeted molecular therapy for neuroblastoma, Medicine, DNA, Genomics, Food safety, DSM-IV codes, Partnership, Research, Neurology, PCR, Genetic testing, Health, Vaccine

CleanPlex is a proprietary, ultra-high multiplexed target enrichment technology for NGS-based assays for research and diagnostic testing.

Key Points: 
  • CleanPlex is a proprietary, ultra-high multiplexed target enrichment technology for NGS-based assays for research and diagnostic testing.
  • Tao Chen, Chief Executive Officer of Paragon Genomics, said, "We are delighted that Devyser is bringing our unique CleanPlex technology to their customers in Italy.
  • Virginio Marra, CEO of Devyser Italy, commented, "We are excited to partner with Paragon Genomics to distribute their innovative CleanPlex technology in Italy.
  • Paragon Genomics' CleanPlex is a proprietary, ultra-high multiplexed NGS target enrichment technology that makes it possible to include a large number of genomic targets in a single assay.